Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Bioorg Med Chem ; 24(11): 2410-22, 2016 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-27117260

RESUMEN

Although many compounds have been approved for the treatment of human immunodeficiency type-1 (HIV-1) infection, additional anti-HIV-1 drugs (particularly those belonging to new drug classes) are still needed due to issues such as long-term drug-associated toxicities, transmission of drug-resistant variants, and development of multi-class resistance. Lethal mutagenesis represents an antiviral strategy that has not yet been clinically translated for HIV-1 and is based on the use of small molecules to induce excessive levels of deleterious mutations within the viral genome. Here, we show that 5-azacytidine (5-aza-C), a ribonucleoside analog that induces the lethal mutagenesis of HIV-1, and multiple inhibitors of the enzyme ribonucleotide reductase (RNR) interact in a synergistic fashion to more effectively reduce the infectivity of HIV-1. In these drug combinations, RNR inhibitors failed to significantly inhibit the conversion of 5-aza-C to 5-aza-2'-deoxycytidine, suggesting that 5-aza-C acts primarily as a deoxyribonucleoside even in the presence of RNR inhibitors. The mechanism of antiviral synergy was further investigated for the combination of 5-aza-C and one specific RNR inhibitor, resveratrol, as this combination improved the selectivity index of 5-aza-C to the greatest extent. Antiviral synergy was found to be primarily due to the reduced accumulation of reverse transcription products rather than the enhancement of viral mutagenesis. To our knowledge, these observations represent the first demonstration of antiretroviral synergy between a ribonucleoside analog and RNR inhibitors, and encourage the development of additional ribonucleoside analogs and RNR inhibitors with improved antiretroviral activity.


Asunto(s)
Fármacos Anti-VIH/farmacología , Azacitidina/farmacología , Inhibidores Enzimáticos/farmacología , Infecciones por VIH/tratamiento farmacológico , VIH-1/efectos de los fármacos , Ribonucleótido Reductasas/antagonistas & inhibidores , Fármacos Anti-VIH/síntesis química , Fármacos Anti-VIH/química , Azacitidina/síntesis química , Azacitidina/química , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Humanos , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Ribonucleótido Reductasas/metabolismo , Relación Estructura-Actividad
2.
Artículo en Inglés | MEDLINE | ID: mdl-26167665

RESUMEN

This paper presents the results of synthesis and study of cytotoxicity and the anti-adenoviral activity of new N4-derivatives of 6-azacytidine and its α-L-glycopyranosyl analogues obtained by the simplified one-pot version of the silyl condensation method. The resulting acylated 4-methylmercapto-1,2,4-triazin-3(2Н)-one glycosides then underwent the amination and/or ammonolysis to provide 6-azacytidine glycoside analogues (2-6, 12, 15, 17) and compounds with modifications at both base and sugar fragments (11, 15). The evaluation of cytotoxicity and antiviral activity of new compounds against AdV5 showed high selectivity indexes for N4-methyl-6-azacytidine (2) and N,O-tetraacetyl-6-azacytidine (8). High anti-adenoviral activity of N4-methyl-6-azacytidine as well as very low cytotoxicity may suggest its further investigation as potential compound for the therapy of AdV infection.


Asunto(s)
Adenoviridae/efectos de los fármacos , Antivirales/síntesis química , Antivirales/farmacología , Azacitidina/análogos & derivados , Azacitidina/síntesis química , Azacitidina/farmacología , Células Cultivadas , Efecto Citopatogénico Viral/efectos de los fármacos , Humanos , Replicación Viral/efectos de los fármacos
3.
J Pharm Biomed Anal ; 50(5): 847-52, 2009 Dec 05.
Artículo en Inglés | MEDLINE | ID: mdl-19660889

RESUMEN

A controlled azacytidine release system based on drug encapsulation with a polymer material has been prepared and characterized. The drug systems were prepared by precipitation from solutions, using supercritical CO2 antisolvent technique operating in a semi-continuous mode. Azacytidine was dissolved in dimethylsulfoxide and poly-lactic acid in methylene chloride. The two solutions were mixed before being sprayed into the supercritical reactor. Experimental conditions were 40 degrees C for temperature, 11 MPa for pressure, and a CO2 flow rate of 30 ml min(-1). The precipitated drug-polymer particles were further characterized to determine the percentage of encapsulated drug and establish the delivery kinetics under various release conditions. A sustained delivery of the drug over a period of various hours was obtained. Besides, an improved stability of the coated drug with respect to the pure azacytidine was found, thus proving the suitability of this approach for dealing with unstable compounds.


Asunto(s)
Azacitidina/química , Azacitidina/síntesis química , Química Farmacéutica/métodos , Ácido Láctico/química , Ácido Láctico/síntesis química , Polímeros/química , Polímeros/síntesis química , Dióxido de Carbono/química , Cromatografía/métodos , Dimetilsulfóxido/química , Sistemas de Liberación de Medicamentos , Diseño de Equipo , Concentración de Iones de Hidrógeno , Cinética , Cloruro de Metileno/química , Tamaño de la Partícula , Poliésteres , Presión , Solventes/química , Temperatura
4.
Appl Biochem Biotechnol ; 151(1): 21-8, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18785019

RESUMEN

Enzymatic regioselective acylation of 5-azacytidine with vinyl laurate was successfully conducted with an immobilized lipase from Candida antarctica type B (i.e., Novozym 435) for the first time. The acylation of 5-azacytidine took place at its primary hydroxyl group and the desired product 5'-O -lauroyl-5-azacytidine could be prepared with high reaction rate, high conversion, and excellent regioselectivity. The influences of several key variables on the enzymatic acylation were also systematically examined. Pyridine was found to be the best reaction medium. The optimum initial water activity, the molar ratio of vinyl laurate to 5-azacytidine and reaction temperature were 0.07, 30:1, and 50 degrees C, respectively. Under the optimized conditions described above, the initial reaction rate, the substrate conversion, and the regioselectivity were as high as 0.58 mM/min, 95.5%, and >99%, respectively, after a reaction time of around 5 h.


Asunto(s)
Azacitidina/síntesis química , Lauratos/química , Lipasa/química , Catálisis , Enzimas Inmovilizadas/química , Proteínas Fúngicas , Isomerismo
5.
Molecules ; 13(7): 1487-500, 2008 Jul 23.
Artículo en Inglés | MEDLINE | ID: mdl-18719520

RESUMEN

Twenty-six 5-azacytidine analogues have been synthesized, including 4-amino- 6-alkyl-1-pyranosyl/ribofuranosyl-1,3,5-triazin-2(1H)-ones 1a-j, 6-amino-4-alkyl/aryl-1- pyranosyl/ribofuranosyl-1,3,5-triazin-2(1H)-ones 2a-f and 4-amino-6-alkyl-1,3,5-triazin-2- yl-1-thio-pyranosides/ribofuranosides 3a-j. The antiproliferative activities of these synthetic analogues were investigated in human leukemia HL-60 cells. Ribofuranosyl S-nucleoside 3a, a bioisostere of 5-azacytidine, had a similar antiproliferative ability as that of the latter. Introduction of a methyl at the 6 position of 5-azacytidine and/or replacement of the ribofuranosyl moiety with pyranosyl sugars or disaccharides significantly decreased the antiproliferative activities of the 5-azacytidine derivatives. Several compounds with the replacement of pyranosyl sugars enhanced all-trans retinoic acid-induced differentiation ability in human leukemia HL-60 cells.


Asunto(s)
Azacitidina/análogos & derivados , Proliferación Celular/efectos de los fármacos , Inhibidores de Crecimiento/síntesis química , Inhibidores de Crecimiento/farmacología , Leucemia/tratamiento farmacológico , Antimetabolitos Antineoplásicos/síntesis química , Antimetabolitos Antineoplásicos/farmacología , Azacitidina/síntesis química , Azacitidina/farmacología , Células HL-60 , Humanos , Leucemia/patología
8.
Nucleosides Nucleotides Nucleic Acids ; 22(12): 2161-70, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14714764

RESUMEN

1-O-Acetyl-2-deoxy-3,5-di-O-toluoyl-4-thio-D-erythro-pentofuranose and 2-deoxy-1,3,5-tri-O-acetyl-4-thio-L-threo-pentofuranose were coupled with 5-azacytosine to obtain alpha and beta anomers of nucleosides. All four nucleosides were reduced to the corresponding dihydro derivatives and deblocked to give target compounds. All eight target compounds were evaluated in a series of human cancer cell lines in culture. Only 2'-deoxy-4'-thio-5-azacytidine (3beta) was found to be cytotoxic in all the cell lines and was further evaluated in vivo. Details of the synthesis and biological activity are reported.


Asunto(s)
Azacitidina/análogos & derivados , Citosina/análogos & derivados , Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Azacitidina/síntesis química , Azacitidina/farmacología , Conformación de Carbohidratos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Citidina/análogos & derivados , Citosina/química , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Espectroscopía de Resonancia Magnética , Estructura Molecular , Pentosas/química , Nucleósidos de Pirimidina/síntesis química , Nucleósidos de Pirimidina/farmacología , Compuestos de Azufre/química
9.
Artículo en Inglés | MEDLINE | ID: mdl-11563127

RESUMEN

2'-Deoxy-beta-L-5-azacytidine(L-Decitabine), beta-L-5-azacytidine, and derivatives were stereospecifically prepared starting from L-ribose or L-xylose. D- and L-enantiomers of 2'-deoxy-beta-5-azacytidine were weak substrates of human recombinant deoxycytidine kinase (dCK), whereas both enantiomers of beta-5-azacytidine or the L-xylo-analogues were not substrates of the enzyme. None of the reported derivatives of beta-L-5-azacytidine was a substrate of human recombinant cytidine deaminase (CDA).


Asunto(s)
Azacitidina/análogos & derivados , Azacitidina/metabolismo , Desoxicitidina Quinasa/metabolismo , Azacitidina/síntesis química , Azacitidina/química , Decitabina , Desoxicitidina Quinasa/química , Humanos , Estereoisomerismo , Especificidad por Sustrato
10.
Eur J Med Chem ; 35(11): 1011-9, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11137229

RESUMEN

Although 2'-deoxy-beta-D-5-azacytidine (Decitabine) and beta-D-5-azacytidine display potent antileukemic properties, their therapeutic use is hampered by their sensitivity to nucleophiles and to deamination catalysed by cytidine deaminase. As shown earlier [Shafiee M., Griffon J.-F., Gosselin G., Cambi A., Vincenzetti S., Vita A., Erikson S., Imbach J.-L., Maury G., Biochem. Pharmacol. 56 (1998) 1237-1242], beta-L-enantiomers of cytidine derivatives are resistant to cytidine deaminase. We thus synthesized several 5-azacytosine beta-L-nucleoside analogues to evaluate their enzymatic and biological properties. 2'-Deoxy-beta-L-5-azacytidine (L-Decitabine), beta-L-5-azacytidine, 1-(beta-L-xylo-furanosyl)5-azacytosine, and 1-(2-deoxy-beta-L-threo-pentofuranosyl)5-azacytosine were stereospecifically prepared starting from L-ribose and L-xylose. D- and L-enantiomers of 2'-deoxy-beta-5-azacytidine were weak substrates of human recombinant deoxycytidine kinase (dCK) compared to beta-D-deoxycytidine, whereas both enantiomers of beta-5-azacytidine or the L-xylo-analogues were not substrates of the enzyme. As expected, none of the presently reported derivatives of beta-L-5-azacytidine was a substrate of human recombinant cytidine deaminase (CDA). The prepared compounds were tested for their activity against HIV and HBV and they did not show any significant activity or cytotoxicity. In the case of L-Decitabine, this suggests that the enantioselectivities of concerned enzymes other than dCK and CDA might not be favourable.


Asunto(s)
Azacitidina/síntesis química , Azacitidina/farmacología , Antivirales/síntesis química , Antivirales/química , Antivirales/farmacología , Azacitidina/química , Desoxicitidina Quinasa/metabolismo , Virus de Hepatitis/efectos de los fármacos , Humanos , Cinética , Análisis Espectral , Estereoisomerismo
11.
Biochemistry ; 24(18): 4806-14, 1985 Aug 27.
Artículo en Inglés | MEDLINE | ID: mdl-2416336

RESUMEN

Deoxy-5-azacytidine 5'-triphosphate was synthesized and used as a substrate for the enzymatic synthesis of the polynucleotide poly[d(G-z5C)]. Whereas the triphosphate decomposes in solution, the azacytosine analogue incorporated into DNA is stable under conditions preserving the double-helical structure. Poly[d(G-z5C)] undergoes the transition to the left-handed Z conformation at salt (NaCl and MgCl2) concentrations approximately 30% higher than those required for unsubstituted poly[d(G-C)]. However, the incorporation of azacytidine potentiates the formation at room temperature of the Z helix stabilized by the transition metal Mn2+; in the case of poly[d(G-C)], a heating step is required. The spectral properties of the two polymers in the B and Z forms are similar. Both left-handed forms are recognized by anti-Z DNA immunoglobulins, indicating that the DNAs bear common antigenic features. Poly[d(G-z5C)] is not a substrate for the DNA cytosine 5-methyltransferase from human placenta. It is a potent inhibitor of the enzyme when tested in a competitive binding assay. These results are compatible with a very strong, possibly covalent, mode of interaction between methyltransferases and DNA containing 5-azacytosine.


Asunto(s)
ADN (Citosina-5-)-Metiltransferasas/antagonistas & inhibidores , Polidesoxirribonucleótidos/síntesis química , Azacitidina/análogos & derivados , Azacitidina/síntesis química , Citidina Trifosfato/análogos & derivados , Citidina Trifosfato/síntesis química , Femenino , Humanos , Indicadores y Reactivos , Cinética , Conformación de Ácido Nucleico , Placenta/enzimología , Polidesoxirribonucleótidos/farmacología , Embarazo , Espectrofotometría Ultravioleta
12.
Nucleic Acids Res ; 12(12): 5025-36, 1984 Jun 25.
Artículo en Inglés | MEDLINE | ID: mdl-6204276

RESUMEN

5-azacytidine-5'-triphosphate prepared from 5-azacytidine by chemical phosphorylation is a substrate for AMP (CMP) tRNA nucleotidyl transferase from yeast. tRNAsPhe from yeast containing 5-azacytidine in their 3'-termini were prepared enzymatically. tRNAPhe-Cpn5CpA and tRNAPhe-n5Cpn5CpA can be aminoacylated by phenylalanyl-tRNA synthetase from yeast and they are active in the poly(U)-dependent synthesis of poly(Phe) on E. coli ribosomes. The decomposition of 5-azacytidine via hydrolysis of the triazine ring is significantly accelerated by a phosphate group on the 5'-position of the nucleotide. After the incorporation of 5-azacytidine-5'-phosphate into a polynucleotide chain the rate of hydrolysis of the triazine ring decreases considerably.


Asunto(s)
Azacitidina/análogos & derivados , Citidina Monofosfato/análogos & derivados , Citidina Trifosfato/análogos & derivados , Nucleótidos de Citosina , ARN de Transferencia/síntesis química , Azacitidina/síntesis química , Citidina Monofosfato/síntesis química , Citidina Trifosfato/síntesis química , Escherichia coli/metabolismo , Indicadores y Reactivos , Cinética , Fenilalanina-ARNt Ligasa/metabolismo , Fosforilación , Biosíntesis de Proteínas , ARN Nucleotidiltransferasas/metabolismo , ARN de Transferencia/genética , Ribosomas/metabolismo
13.
Nucleic Acids Symp Ser ; (9): 83-6, 1981.
Artículo en Inglés | MEDLINE | ID: mdl-6170945

RESUMEN

The stannic chloride catalyzed glycosylation of bis-tri-methylsilyl-6-methyl-5-azacytosine 2 with the halogenose 3 leading to the protected anomeric nucleosides 4a and 4b was investigated. Methanolysis of 4a and 4b afforded the corresponding free nucleosides 1a and 1b. Compounds 4a and 4b were also prepared by the isocyanate method via acetylamidinourea derivatives 6. Antileukemic activity in vitro and inhibition of growth of E. coli by the title compounds are reported.


Asunto(s)
Azacitidina/análogos & derivados , Animales , Azacitidina/síntesis química , Azacitidina/farmacología , Azacitidina/uso terapéutico , Evaluación Preclínica de Medicamentos , Escherichia coli/efectos de los fármacos , Indicadores y Reactivos , Neoplasias Experimentales/tratamiento farmacológico
15.
J Med Chem ; 22(10): 1230-4, 1979 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-92567

RESUMEN

5-Azacytosine arabinoside (ara-AC) can be considered a combination of structural elements derived from the antitumor nucleosides cytosine arabinoside (ara-C) and 5-azacytidine (5-AC). The synthesis of ara-AC, for which standard methods were inadequate, was accomplished using the stable dihydro derivative as a synthetic intermediate. A novel dehydrogenation of the latter through the application of a trimethylsilylation-oxidation procedure gave ara-AC in good yield. Using murine L1210 leukemia as a test system, ara-AC was evaluated for antitumor properties in parallel determinations with 5-AC and ara-C. Although higher dose levels were necessary, ara-AC demonstrated a reproducibly greater efficacy in the L1210 system (% ILS = 144-148) than that shown by 5-AC (% ILS = 126-124) or ara-C (% ILS=127-121 ). Moreover, initial data suggest that ara-AC exhibits less host toxicity than either 5-AC or ARA-C. Although ara-AC can equally be considered an analogue of either 5-AC or ara-C, preliminary results indicate that ara-AC is chemically similar to 5-AC but biologically more closely related to ara-C.


Asunto(s)
Antineoplásicos/síntesis química , Azacitidina/síntesis química , Animales , Antineoplásicos/uso terapéutico , Azacitidina/farmacología , Fenómenos Químicos , Química , Leucemia L1210/tratamiento farmacológico , Ratones , Estereoisomerismo
18.
J Med Chem ; 20(4): 598-600, 1977 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-66316

RESUMEN

5-Azacytidine (1) labeled with 13C or 14C at the chemically labile C-6 position was synthesized. A method utilizing hydrolytic opening of the triazine ring followed by recyclization with dimethylformamide dimethyl acetal was used. Urinary and biliary excretion was measured in rabbits following intravenous doses of 1-4-14C and 1-6-14C. Differences in recoveries of the dose from 4-14C and 6-14C demonstrate that ring cleavage of 1 with loss of the C-6 carbon represents a major metabolite route.


Asunto(s)
Azacitidina/síntesis química , Isótopos de Carbono , Radioisótopos de Carbono , Marcaje Isotópico , Animales , Azacitidina/metabolismo , Azacitidina/orina , Bilis/metabolismo , Masculino , Métodos , Conejos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA